Market revenue in 2024 | USD 7,997.6 million |
Market revenue in 2030 | USD 15,161.7 million |
Growth rate | 11.3% (CAGR from 2025 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Diagnostics |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Diagnostics, Therapeutics |
Key market players worldwide | Thermo Fisher Scientific Inc, Invitae Corp, Qiagen NV, Illumina Inc, Exact Sciences Corp, Rain Oncology, Strata Oncology, Xilis, Variantyx, BioServe, Relay Therapeutics, Acrivon Therapeutics |
Therapeutics was the largest segment with a revenue share of 79% in 2024. Horizon Databook has segmented the Japan precision oncology market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
The precision oncology market in Japan is anticipated to grow at a significant CAGR during the forecast period. Japan’s investment in research and development, particularly in biotechnology and diagnostics, supports continuous innovation and market growth.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account